Arvinas ARVN
NASDAQ ARVN
$9.41 +0.10 (+1.07%)
As of: Sep 4, 2026 · 3:21 PM EDT

Arvinas (ARVN) Cash from Investing Activities (2017 - 2026)

Arvinas (ARVN) posted quarterly Cash from Investing Activities of $13.7 million for Q1 2026, down 80.29% year-over-year from $69.5 million in Q1 2025, and down 90.6% quarter-over-quarter from $145.8 million in Q4 2025.

Analysis

Arvinas (ARVN) Cash from Investing Activities (2017 - 2026) Analysis & Trends

Arvinas' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $13.7 million for Q1 2026.

  • In Q1 2026, Cash from Investing Activities fell 80.29% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $351.8 million (up 51.64% YoY), while the FY2025 annual figure was $407.6 million, up 1074.64% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at $13.7 million, down from $145.8 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $145.8 million in Q4 2025, with the low at -$127.8 million in Q1 2024.
  • The 5-year median for Cash from Investing Activities is $63.5 million (2025), against an average of $53.1 million.
  • Peak annual rise in Cash from Investing Activities reached 1511.63% in 2023, while the deepest fall reached 376.8% in 2023.
  • Arvinas' Cash from Investing Activities stood at $19.4 million in 2022, then sank by 376.8% to -$53.7 million in 2023, then jumped by 284.17% to $98.9 million in 2024, then soared by 47.42% to $145.8 million in 2025, then slumped by 90.6% to $13.7 million in 2026.
  • Business Quant data shows ARVN's Cash from Investing Activities at $13.7 million in Q1 2026, $145.8 million in Q4 2025, and $63.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.37 Bn 130.52 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.18 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.33 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.92 Bn 52.78 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - -1.66 Bn
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.48 Bn 32.17 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn - -229.72 Mn
9 Insmed 27.38 Bn 26.22 Bn 358.27 Mn 24.51 Mn
10 Arvinas 609.77 Mn 41.87 Mn - 54.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 54.90 Mn
Mar 31, 2026 13.70 Mn
Dec 31, 2025 145.80 Mn
Sep 30, 2025 63.50 Mn
Jun 30, 2025 128.80 Mn
Mar 31, 2025 69.50 Mn
Dec 31, 2024 98.90 Mn
Sep 30, 2024 50.50 Mn
Jun 30, 2024 13.10 Mn
Mar 31, 2024 -127.80 Mn
Dec 31, 2023 -53.70 Mn
Sep 30, 2023 70.00 Mn
Jun 30, 2023 48.60 Mn
Mar 31, 2023 138.60 Mn
Dec 31, 2022 19.40 Mn
Sep 30, 2022 105.80 Mn
Jun 30, 2022 109.00 Mn
Mar 31, 2022 8.60 Mn
Dec 31, 2021 -115.60 Mn
Sep 30, 2021 -741.10 Mn